PD‐L1 is preferred to PD‐1 as a predictive biomarker of immunotherapy response since its expression is more reliably detected with IHC and unlike PD‐1, which is assessed only in inflammatory cells, PD‐L1 can be detected on both tumor and inflammatory cells. The gene discussed is CD274; the disease is neoplasm.